MP28-14 Real-World Survival Outcomes Associated With Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Papillary Renal Cell Carcinoma

Abstract

You have accessJournal of UrologyErrata1 Jul 2023MP28-14 Real-World Survival Outcomes Associated With Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Papillary Renal Cell Carcinomais correction ofMP28-14 REAL-WORLD SURVIVAL OUTCOMES ASSOCIATED WITH IMMUNOTHERAPY, TARGETED THERAPY, AND COMBINATION THERAPY FOR METASTATIC PAPILLARY RENAL CELL CARCINOMA View All Author Informationhttps://doi.org/10.1097/JU.0000000000003517AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Volume 209, Supplement 4, Page e376: The eighth through 14th authors’ names are Monica Morgan, Brian J. Miles, Taliah Muhammad, Maryam Anis, Monty Aghazadeh, Jun Zhang, and Eleni Efstathiou, and the 17th author’s name is Brian Rini. The online and PDF versions of the article have been updated. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of Urology23 Mar 2023MP28-14 REAL-WORLD SURVIVAL OUTCOMES ASSOCIATED WITH IMMUNOTHERAPY, TARGETED THERAPY, AND COMBINATION THERAPY FOR METASTATIC PAPILLARY RENAL CELL CARCINOMA Volume 210Issue 1July 2023Page: 224-224 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Expand All Advertisement Advertisement PDF downloadLoading ...